Analysts See $-0.01 EPS for Arch Therapeutics, Inc. (ARTH)

November 10, 2018 - By Jeanette Kaplan

Arch Therapeutics, Inc. (OTCMKTS:ARTH) Logo

Analysts expect Arch Therapeutics, Inc. (OTCMKTS:ARTH) to report $-0.01 EPS on November, 21. The stock 1.30% or $0 during the last trading session, reaching $0.39. It is down 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Arch Therapeutics, Inc. operates as a life science medical device company. The company has market cap of $62.61 million. The firm develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. It currently has negative earnings. The Company’s primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.